BRIEF published on 11/06/2024 at 09:48, 15 days ago Crossing of thresholds by Invus Public Equities in GENEURO SA Euronext Paris Capital Increase Crossing Thresholds GeNeuro SA Invus Public Equities
BRIEF published on 11/06/2024 at 09:48, 15 days ago Franchissement de seuils par Invus Public Equities dans GENEURO SA Euronext Paris Augmentation De Capital Franchissement De Seuils GeNeuro SA Invus Public Equities
PRESS RELEASE published on 11/06/2024 at 09:43, 15 days ago Franchissement de seuils Déclaration de franchissement de seuils par Invus Public Equities, LP. concernant GENEURO SA sur Euronext Paris Euronext Paris Déclaration Franchissement De Seuils GeNeuro SA Invus Public Equities
BRIEF published on 06/28/2024 at 07:05, 4 months 23 days ago GeNeuro announces the results of the GNC-501 trial in post-Covid-19 syndrome Business Strategy Clinical Test GeNeuro Temelimab Post-Covid-19 Syndrome
BRIEF published on 06/28/2024 at 07:05, 4 months 23 days ago GeNeuro annonce les résultats de l’essai GNC-501 dans le syndrome post-Covid-19 Stratégie D'entreprise Essai Clinique GeNeuro Temelimab Syndrome Post-Covid-19
PRESS RELEASE published on 06/28/2024 at 07:00, 4 months 23 days ago Inside Information / Other news releases GeNeuro announces results of the GNC-501 study addressing post-COVID-19 neuropsychiatric syndromes. Initial findings show no significant improvement with temelimab treatment compared to placebo GeNeuro Temelimab Neuropsychiatric Post-Covid-19 Syndrome GNC-501 Study
PRESS RELEASE published on 06/28/2024 at 07:00, 4 months 23 days ago Informations privilégiées / Autres communiqués GeNeuro annonce les résultats de l’essai GNC-501 dans le syndrome post-Covid-19. Analyse des effets du temelimab chez des patients post-COVID-19. Réduction des coûts et effectifs chez GeNeuro GeNeuro Temelimab Syndrome Post-Covid-19 GNC-501 Réduction Coûts
BRIEF published on 06/14/2024 at 18:35, 5 months 6 days ago GeNeuro annonce l'approbation unanime des résolutions lors de l'AGA Actionnaires Biopharmaceutique Resolutions AGA GeNeuro
BRIEF published on 06/14/2024 at 18:35, 5 months 6 days ago GeNeuro Announces Unanimous Approval of Resolutions at AGM Shareholders Biopharmaceutical AGM Resolutions GeNeuro
PRESS RELEASE published on 06/14/2024 at 18:30, 5 months 6 days ago Inside Information / Other news releases GeNeuro shareholders approve all resolutions proposed at 2024 AGM, including annual report, re-election of Board members, and compensation approval. 81.54% share capital represented at the meeting Shareholders Compensation AGM Resolutions GeNeuro
Published on 11/21/2024 at 09:00, 59 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 24 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 34 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 59 minutes ago Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 59 minutes ago Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates
Published on 11/21/2024 at 09:41, 18 minutes ago Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/21/2024 at 08:59, 59 minutes ago Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 59 minutes ago Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 44 minutes ago EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 06:58, 3 hours 1 minute ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours 1 minute ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours 1 minute ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 51 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 39 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
